Horizon Therapeutics plc announced findings of a real-world adherence analysis of Tepezza for the treatment of TED ( Thyroid Eye Disease) at the American Academy of Ophthalmology Annual… read more.
Clinical trial planning underway to test the widely used diabetes drug metformin as a preventive treatment for the blinding eye disease. Scientists have discovered that gene therapy and… read more.
Oregon Health & Science University is part of a national research project investigating stem cell therapy as a potential treatment for glaucoma, the world’s second leading cause of blindness…. read more.
Allergan announced the FDA approval of Vuity (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. Vuity is… read more.
Oyster Point Pharma, Inc. announced that the FDA has approved Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye… read more.
Risk of dementia increases with age-related macular degeneration, cataract and diabetes-related eye disease, but not glaucoma. Age-related macular degeneration, cataract and diabetes-related eye disease are linked to an… read more.
Horizon Therapeutics plc has announced that the first patient has been enrolled in a Phase IV clinical trial evaluating the efficacy and safety of Tepezza for the treatment… read more.
In the paper published in EClinical Medicine by The Lancet, the research team examined lesions of the retina, the inner-most, light-sensitive layer of the eye, to determine if a cardiovascular… read more.
Women who currently use hormonal contraceptives face more than a 2-fold higher risk of developing glaucoma, according to an analysis of electronic medical records for women aged 15-45… read more.
A simple eye exam combined with powerful artificial intelligence (AI) machine learning technology could provide early detection of Parkinson’s disease, according to research being presented at the annual… read more.
by Bruce Sylvester: One dosing with methylene blue appears to increase MRI-based response in brain areas that control short-term memory and attention, researchers reported on June 28 in… read more.
by Bruce Sylvester: Investigators from a phase l/II clinical trial report that high-dose atorvastatin treatment of patients with the dry form of age-related macular degeneration (AMD) resulted in… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
